<DOC>
	<DOC>NCT01396148</DOC>
	<brief_summary>Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients. In addition, tumor responses and overall survival will be assessed.</brief_summary>
	<brief_title>A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological diagnosis of GIST. Patients must have demonstrated either disease progression or intolerance to imatinib mesylate, have nonmutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain imatinib in their country Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease. Current treatment with another investigational agent. Prior sunitinib treatment. Prior therapy with known risk for cardiovascular complications.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Children and young adults with GIST</keyword>
	<keyword>sunitinib malate</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tumor response</keyword>
	<keyword>overall survival</keyword>
	<keyword>tumor KIT mutation status</keyword>
</DOC>